참고문헌
- Vellingiri B, Jayaramayya K, Iyer M et al (2020) COVID-19: A promising cure for the global panic. Sci Total Environ 725, 138277 https://doi.org/10.1016/j.scitotenv.2020.138277
- Iyer M, Jayaramayya K, Subramaniam MD et al (2020) COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep 53, 191-205 https://doi.org/10.5483/bmbrep.2020.53.4.080
- Grasselli G, Zangrillo A, Zanella A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323, 1574-1581 https://doi.org/10.1001/jama.2020.5394
- Sun X, Wang T, Cai D et al (2020) Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2020.04.002
- Balachandar V, Mahalaxmi I, Devi SM et al (2020) Follow-up studies in COVID-19 recovered patients-is it mandatory? Sci Total Environ 729, 139021 https://doi.org/10.1016/j.scitotenv.2020.139021
- Taghavi-farahabadi, M, Mahmoudi M, Soudi S and Hashemi SM (2020) Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cellderived exosomes. Med Hypotheses 144, 109865 https://doi.org/10.1016/j.mehy.2020.109865
- Li G, Fan Y, Lai Y et al (2020) Coronavirus infections and immune responses. J Med Virol 92, 424-432 https://doi.org/10.1002/jmv.25685
- Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. doi: 10.1093/cid/ciaa248
- Wang W, He J and Wu S (2020) The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. doi: https://doi.org/10.1101/2020.02.26.20026989
- Tufan A, Guler AA and Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50, 620-632 https://doi.org/10.3906/sag-2004-168
- Sakaguchi S, Miyara M, Costantino CM and Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10, 490-500 https://doi.org/10.1038/nri2785
- Zbinden-Foncea H, Francaux M, Deldicque L and Hawley JA (2020) Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity. doi: 10.1002/oby.22849
- Shneider A, Kudriavtsev A and Vakhrusheva A (2020) Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol 39, 153-162 https://doi.org/10.1080/08830185.2020.1756284
- Guo J, Huang Z, Lin L and Lv J (2020) Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 9, e016219
- Conti P, Ronconi G, Caraffa A et al (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34, 1
- Zhao Q, Ren H and Han Z (2016) Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother 2, 3-20 https://doi.org/10.1016/j.jocit.2014.12.001
- Prockop DJ (2017) The exciting prospects of new therapies with mesenchymal stromal cells. Cytotherapy 19, 1-8 https://doi.org/10.1016/j.jcyt.2016.09.008
- Wilson JG, Liu KD, Zhuo H et al (2015) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3, 24-32 https://doi.org/10.1016/S2213-2600(14)70291-7
- Uccelli A, Moretta L and Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8, 726-736 https://doi.org/10.1038/nri2395
- Ren G, Zhang L, Zhao X et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150 https://doi.org/10.1016/j.stem.2007.11.014
- Waterman RS, Tomchuck SL, Henkle SL and Betancourt AM (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5, e10088 https://doi.org/10.1371/journal.pone.0010088
-
Patel SA, Meyer JR, Greco SJ, Corcoran KE and Bryan M, Rameshwar P (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-
${\beta}$ . J Immunol 184, 5885-5894 https://doi.org/10.4049/jimmunol.0903143 - Raffaghello L, Bianchi G, Bertolotto M et al (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26, 151-162 https://doi.org/10.1634/stemcells.2007-0416
- Thanunchai M, Hongeng S and Thitithanyanont A (2015) Mesenchymal stromal cells and viral infection. Stem Cells Int 2015, 860950
- Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML and Corsico AG (2020) Mesenchymal stromal cell secretome for severe COVID-19 infections: Premises for the therapeutic use. Cells 9, 924 https://doi.org/10.3390/cells9040924
- Crivelli B, Chlapanidas T, Perteghella S et al (2017) Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J Controlled Release 262, 104-117 https://doi.org/10.1016/j.jconrel.2017.07.023
- Deffune E, Prudenciatti A and Moroz A (2020) Mesenchymal stem cell (MSc) secretome: a possible therapeutic strategy for intensive-care COVID-19 patients. Med Hypotheses 142, 109769 https://doi.org/10.1016/j.mehy.2020.109769
- Keshtkar S, Azarpira N and Ghahremani MH (2018) Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther 9, 63 https://doi.org/10.1186/s13287-018-0791-7
- Lou G, Chen Z, Zheng M and Liu Y (2017) Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med 49, e346-e346 https://doi.org/10.1038/emm.2017.63
- Lai P, Chen X, Guo L et al (2018) A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol 11, 135 https://doi.org/10.1186/s13045-018-0680-7
- Alvarez V, Sanchez-Margallo FM, Macias-Garcia B et al (2018) The immunomodulatory activity of extracellular vesicles derived from endometrial mesenchymal stem cells on CD4+ T cells is partially mediated by TGFbeta. J Tissue Eng Regen Med 12, 2088-2098
- Fan Y, Herr F, Vernochet A, Mennesson B, Oberlin E and Durrbach A (2019) Human fetal liver mesenchymal stem cell-derived exosome impair natural killer cell function. Stem Cells Dev 28, 44-55 https://doi.org/10.1089/scd.2018.0015
- Domenis R, Cifu A, Quaglia S et al (2018) Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. Sci Rep 8, 13325 https://doi.org/10.1038/s41598-018-31707-9
-
Song Y, Dou H, Li X et al (2017) Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-
$1{\beta}$ -primed mesenchymal stem cells against sepsis. Stem Cells 35, 1208-1221 https://doi.org/10.1002/stem.2564 - Chen W, Huang Y, Han J et al (2016) Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol Res 64, 831-840 https://doi.org/10.1007/s12026-016-8798-6
- Ji L, Bao L, Gu Z et al (2019) Comparison of immunomodulatory properties of exosomes derived from bone marrow mesenchymal stem cells and dental pulp stem cells. Immunol Res 67, 432-442 https://doi.org/10.1007/s12026-019-09088-6
- He Ping (2019) AB0291E the effect of human umbilical cord mesenchymal stem cells-derived exosomes on chemokines in collagen-induced arthritis rats. BMJ 1606-1606
- Mardpour S, Hamidieh AA, Taleahmad S, Sharifzad F, Taghikhani A and Baharvand H (2019) Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. J Cellular Physiol 234, 8249-8258 https://doi.org/10.1002/jcp.27669
- Baharlooi H, Azimi M, Salehi Z and Izad M (2020) Mesenchymal stem cell-derived exosomes: A Promising therapeutic ace card to address autoimmune diseases. Int J Stem Cells 13, 13-23 https://doi.org/10.15283/ijsc19108
- Du Y, Zhuansun Y, Chen R, Lin L, Lin Y and Li J (2018) Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. Exp Cell Res 363, 114-120 https://doi.org/10.1016/j.yexcr.2017.12.021
- Fujita Y, Kosaka N, Araya J, Kuwano K and Ochiya T (2015) Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med 21, 533-542 https://doi.org/10.1016/j.molmed.2015.07.004
- Barani B, Rajasingh S and Rajasingh J (2017) Exosomes: Outlook for future cell-free cardiovascular disease therapy. Adv Exp Med Biol 2017, 285-307
- Tsuji K, Kitamura S and Wada J (2018) Secretomes from mesenchymal stem cells against acute kidney injury: possible heterogeneity. Stem Cells Int 2018, 8693137 https://doi.org/10.1155/2018/8693137
- Khatri M, Richardson LA and Meulia T (2018) Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther 9, 17 https://doi.org/10.1186/s13287-018-0774-8
- Chen J, Hu C, Chen L et al (2020) Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering. https://doi.org/10.1016/j.eng.2020.02.006
- Vikram S, Sascha S, Angel L et al (2020) Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 29, 747-754 https://doi.org/10.1089/scd.2020.0080
- Leng Z, Zhu R, Hou W et al (2020) Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11, 216-228 https://doi.org/10.14336/ad.2020.0228
- Clinicaltrials.gov. Cell Therapy Using Umbilical Cordderived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (STROMA-CoV2) ClinicalTrials.gov Identifier: NCT04333368. https://clinicaltrials.gov/ct2/show/NCT04333368?term=Wharton&results?cond=COVIDcovid-19&draw=2&rank=2.term=stem+cell&cntry=&state=&city=&dist=. Accessed on 26th June 2020
- Clinicaltrials.gov. Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19. ClinicalTrials.gov Identifier: NCT04428801. https://clinicaltrials.gov/ct2/show/NCT04428801. Accessed on 26th June 2020
- Clinicaltrials.gov. A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia. ClinicalTrials.gov Identifier: NCT04276987.https://clinicaltrials.gov/ct2/show/NCT04276987. Accessed on 26th June 2020. Accessed on 26th June 2020
- Clinicaltrials.gov. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. ClinicalTrials.gov Identifier: NCT04302519. https://clinicaltrials.gov/ct2/show/NCT04302519. Accessed on 26th June 2020
- Clinicaltrials.gov. Treatment of Covid-19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells. ClinicalTrials.gov Identifier: NCT04382547. https://clinicaltrials.gov/ct2/show/NCT04382547. Accessed on 26th June 2020
- Clinicaltrials.gov. Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019. ClinicalTrials.gov Identifier: NCT04371601.https://clinicaltrials.gov/ct2/show/NCT04371601. Accessed on 26th June 2020
- Clinicaltrials.gov. Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19. ClinicalTrials. gov Identifier: NCT04362189. https://clinicaltrials.gov/ct2/show/NCT04362189. Accessed on 26th June 2020
- Clinicaltrials.gov. Treatment of COVID-19 patients using Wharton's Jelly- Mesenchymal Stem Cells. ClinicalTrials. gov Identifier: NCT04313322. https://clinicaltrials.gov/ct2/show/NCT04313322. Accessed on 16th July 2020
- Clinicaltrials.gov. Safety and Efficacy study of Allogenic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients. ClinicalTrials.gov Identifier: NCT04336254. https://clinicaltrials.gov/ct2/show/NCT04336254. Accessed on 16th July 2020. Accessed on 16th July 2020
- Clinicaltrials.gov. NestCell Mesenchymal Stem Cells to Treat Patients with Severe COVID-19 Pneumonia. ClinicalTrials. gov Identifier: NCT04315987. https://clinicaltrials.gov/ct2/show/NCT04315987.Accessed on 16th July 2020
- Clinicaltrials.gov. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. ClinicalTrials.gov Identifier: NCT04348435. https://clinicaltrials.gov/ct2/show/NCT04348435. Accessed on 16th July 2020
- Clinicaltrials.gov. Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19. ClinicalTrials. gov Identifier: NCT04366323. https://clinicaltrials.gov/ct2/show/NCT04366323. Accessed on 16th July 2020
- Clinicaltrials.gov. A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. ClinicalTrials.gov Identifier: NCT04349631. https://clinicaltrials.gov/ct2/show/NCT04349631. Accessed on 16th July 2020
- Clinicaltrials.gov. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19. Clinical-Trials.gov Identifier: NCT04252118. https://clinicaltrials.gov/ct2/show/NCT04252118. Accessed on 16th July 2020
- Clinicaltrials.gov. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) ClinicalTrials.gov Identifier: NCT04288102 https://clinicaltrials.gov/ct2/show/NCT04288102?term=Treatment+With+Mesenchymal+Stem+Cells++for+Severe+Corona+Virus+Disease+2019+%28COVID-19%29&draw=2&rank=1. Accessed on 16th July 2020
- Clinicaltrials.gov. Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) ClinicalTrials.gov Identifier: NCT04346368. https://clinicaltrials.gov/ct2/show/NCT04346368. Accessed on 16th July 2020
- Clinicaltrials.gov. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19. ClinicalTrials.gov Identifier: NCT04273646. https://clinicaltrials.gov/ct2/show/NCT04273646. Accessed on 16th July 2020
- Clinicaltrials.gov. Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia. ClinicalTrials.gov Identifier: NCT04339660. https://clinicaltrials.gov/ct2/show/NCT04339660. Accessed on 16th July 2020
- Clinicaltrials.gov. Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome. ClinicalTrials.gov Identifier: NCT04366063. https://clinicaltrials.gov/ct2/show/NCT04366063. Accessed on 16th July 2020
- Clinicaltrials.gov. Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19. ClinicalTrials.gov Identifier: NCT04349540. https://clinicaltrials.gov/ct2/show/NCT04349540. Accessed on 16th July 2020
- Clinicaltrials.gov. Use of UC-MSCs for COVID-19 Patients. ClinicalTrials.gov Identifier: NCT04355728. https://clinicaltrials.gov/ct2/show/NCT04355728. Accessed on 16th July 2020
- Clinicaltrials.gov. Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19. ClinicalTrials.gov Identifier: NCT04299152 https://clinicaltrials.gov/ct2/show/NCT04299152.Accessed on 16th July 2020
- Clinicaltrials.gov. Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus ClinicalTrials.gov Identifier: NCT04293692. https://clinicaltrials.gov/ct2/show/NCT04293692. Accessed on 16th July 2020
- Clinicaltrials.gov. Battle Against COVID-19 Using Mesenchymal Stromal Cells. ClinicalTrials.gov Identifier: NCT04348461. https://clinicaltrials.gov/ct2/show/NCT04348461. Accessed on 16th July 2020
- Clinicaltrials.gov. Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS Clinical-Trials.gov Identifier: NCT04331613. https://clinicaltrials.gov/ct2/show/NCT04331613. Accessed on 16th July 2020
- Clinicaltrials.gov. ASC Therapy for Patients With Severe Respiratory COVID-19. ClinicalTrials.gov Identifier: NCT04341610. https://clinicaltrials.gov/ct2/show/NCT04341610. Accessed on 16th July 2020
- Clinicaltrials.gov. Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS). ClinicalTrials.gov Identifier: NCT04377334. https://clinicaltrials.gov/ct2/show/NCT04377334. Accessed on 16th July 2020
- Clinicaltrials.gov. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia. ClinicalTrials.gov Identifier: NCT04269525. https://clinicaltrials.gov/ct2/show/NCT04269525. Accessed on 16th July 2020
- Clinicaltrials.gov. MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) ClinicalTrials.gov Identifier: NCT04367077. https://clinicaltrials.gov/ct2/show/NCT04367077. Accessed on 16th July 2020
- Clinicaltrials.gov. Treatment of Severe COVID-19 Pneumonia with Allogeneic Mesenchymal Stromal Cells (COVID_MSV) Clinical Trials.gov Identifier: NCT04361942. https://clinicaltrials.gov/ct2/show/NCT04361942. Accessed on 16th July 2020
- Clinicaltrials.gov. Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease). ClinicalTrials.gov Identifier: NCT04345601. https://clinicaltrials.gov/ct2/show/NCT04345601. Accessed on 16th July 2020
- Clinicaltrials.gov. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)ClinicalTrials.gov Identifier: NCT03042143. https://clinicaltrials.gov/ct2/show/NCT03042143. Accessed on 16th July 2020
- Clinicaltrials.gov. Mesenchymal Stem Cell Infusion for COVID-19 Infection. ClinicalTrials.gov Identifier: NCT04444271. https://clinicaltrials.gov/ct2/show/NCT04444271. Accessed on 16th July 2020
- Clinicaltrials.gov. Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia (CELMA). ClinicalTrials.gov Identifier: NCT04429763. https://clinicaltrials.gov/ct2/show/NCT04429763. Accessed on 16th July 2020
- Clinicaltrials.gov. Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19). ClinicalTrials.gov Identifier: NCT04416139. https://clinicaltrials.gov/ct2/show/NCT04416139. Accessed on 16th July 2020
-
Clinicaltrials.gov.
$NestaCell^{(R)}$ Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE). ClinicalTrials.gov Identifier: NCT04315987. https://clinicaltrials.gov/ct2/show/NCT04315987. Accessed on 16th July 2020 - Clinicaltrials.gov. Treatment With Human Umbilical Cordderived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19). ClinicalTrials.gov Identifier: NCT04288102. https://clinicaltrials.gov/ct2/show/NCT04288102. Accessed on 16th July 2020
- Clinicaltrials.gov. Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients. ClinicalTrials. gov Identifier: NCT04437823. https://clinicaltrials.gov/ct2/show/NCT04437823. Accessed on 16th July 2020
- Clinicaltrials.gov. Clinical Use of Stem Cells for the Treatment of Covid-19. ClinicalTrials.gov Identifier: NCT 04392778. https://clinicaltrials.gov/ct2/show/NCT04392778. Accessed on 16th July 2020
- Clinicaltrials.gov. Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19. ClinicalTrials.gov Identifier: NCT04390152. https://clinicaltrials.gov/ct2/show/NCT04390152. Accessed on 16th July 2020
- Clinicaltrials.gov. MSCs in COVID-19 ARDS .Clinical Trials.gov Identifier: NCT04371393 https://clinicaltrials.gov/ct2/show/NCT04371393. Accessed on 16th July 2020
- Clinicaltrials.gov. Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDMES). ClinicalTrials.gov Identifier: NCT04390139. https://clinicaltrials.gov/ct2/show/NCT04390139. Accessed on 16th July 2020
- Clinicaltrials.gov. Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard (CIRCA-19). ClinicalTrials.gov Identifier: NCT04400032. https://clinicaltrials.gov/ct2/show/NCT04400032. Accessed on 16th July 2020
- Clinicaltrials.gov. ACT-20 in Patients With Severe COVID-19 Pneumonia. ClinicalTrials.gov Identifier: NCT04398303. https://clinicaltrials.gov/ct2/show/NCT04398303. Accessed on 16th July 2020
- Clinicaltrials.gov. Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation Clinical-Trials.gov Identifier: NCT04397796. https://clinicaltrials.gov/ct2/show/NCT04397796. Accessed on 16th July 2020
- Clinicaltrials.gov. Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19ClinicalTrials.gov Identifier: NCT04389450. https://clinicaltrials.gov/ct2/show/NCT04389450. Accessed on 16th July 2020
- Clinicaltrials.gov. A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy. ClinicalTrials.gov Identifier: NCT04445220 https://clinicaltrials.gov/ct2/show/NCT04445220. Accessed on 16th July 2020
- Kim K, Gil M, Dayem AA et al (2020) Improved isolation and culture of urine-derived stem cells (USCs) and enhanced production of immune cells from the USC-derived induced pluripotent stem cells. J Clin Med 9, 827 https://doi.org/10.3390/jcm9030827
- Kim K, Abdal Dayem A, Gil M et al (2020) 3,2'- Dihydroxyflavone Improves the proliferation and survival of human pluripotent stem cells and their differentiation into hematopoietic progenitor cells. J Clin Med 9, 669 https://doi.org/10.3390/jcm9030669
- Tsuchiya A, Takeuchi S, Iwasawa T et al (2020) Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflammation and Regeneration 40, 1-6 https://doi.org/10.1186/s41232-019-0110-4
- Akkoc T (2020) COVID-19 and mesenchymal stem cell treatment; mystery or not. Adv Exp Med Biol. 1-10 https://doi.org/10.1007/5584_2020_557
- Pinky, Gupta S, Krishnakumar V et al (2020) Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19. Stem Cell Rev Rep 1-11 doi: 10.1007/s12015-020-10002-z
- Muraca M, Pessina A, Pozzobon M et al (2020) Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?. J Control Release 325, 135-140 https://doi.org/10.1016/j.jconrel.2020.06.036
- O'Driscoll L (2020) Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment. Drug Discovery Today. S1359-6446(20)30170-7. https://doi.org/10.1016/j.drudis.2020.04.022
- Sleem A and Saleh F (2020) Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy. Curr Res Transl Med S2452-3186(20)30031-3. doi: 10.1016/j.retram.2020.04.003
- Harrell CR, Jovicic N, Djonov V et al (2020) Therapeutic Use of Mesenchymal Stem Cell-Derived Exosomes: From Basic Science to Clinics. Pharmaceutics 12, 474 https://doi.org/10.3390/pharmaceutics12050474
- Balachandar V, Mahalaxmi I, Kaavya J et al (2020) COVID-19: emerging protective measures. Eur Rev Med Pharmacol Sci 24, 3422-3425